Authors
Xianjie Fu, Ming Li, Chuancai Liu, Yaohui Wu, Junbin Hu, Cong Lu
Published in
Pakistan journal of medical sciences. Volume 42. Issue 8. Pages 2189-2194.
Abstract
At present, there are no reported cases of CD56+ acute myeloid leukemia (AML) combined with hemophagocytic lymphohistiocytosis (HLH). Meanwhile, there is no standardized treatment plan for AML combined with HLH. This article reports a 27 years old female patient with CD56+ AML who received treatment with an HLH-94-based regimen combined with B cell lymphoma 2 (BCL-2) inhibitor venetoclax. After treatment, the patient's body temperature returned to normal and laboratory parameters related to HLH improved. Two weeks after chemotherapy, bone marrow reassessment showed 3% blast cells and undetectable MLL-AF9 fusion transcripts; complete remission was subsequently documented on May 23, 2024. To our knowledge, this represents a rarely reported case of CD56+AML with HLH. The result suggests that BCL-2 targeted therapy combined with HLH-94 regimen may be a safe and promising strategy for treating CD56+AML with HLH, and may provide a basis for the selection of treatment strategies for such patients in clinical practice.
PMID:
42668947
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0